Our findings indicate that the chemotherapeutic regimens employed differentially regulate the expression of ADAM10 and CD58 in ALL.The combination of VCR and MTX consistently induced significant upregulation of both targets at both mRNA and protein levels. The gene discussed is ADAM10; the disease is acute lymphoblastic leukemia.